Medicines Optimisation Centricity
Aspire Pharma initiated and funded a series of workshops run and facilitated by HSJ (previously Wilmington Healthcare). The workshops brought together key NHS and Pharmacy stakeholders to debate and discuss three themes:
It’s Time to Optimise Medicines Optimisation
In March 2023, HSJ Advisory, in partnership with Aspire Pharma Ltd, worked with various NHS experts to discuss the importance of ensuring that the right patient gets the right medicine, at the right dose and time for the right indication, and whether this process is effective and truly patient centric.
The discussions explored and indicated a need for all stakeholders across the NHS and services beyond, including patients themselves, to work more collaboratively to gain optimised medicines optimisation.
Learn more by reading the full thought leadership article:
Reimagining Medicines Optimisation: A Call to Action for Reducing Health Inequalities
In July 2024, HSJ Advisory, in their second partnership with Aspire Pharma Ltd, brought together NHS and pharmacy stakeholders to discuss a critical issue in healthcare: is medicines optimisation contributing to health inequalities? The discussions held during this roundtable highlighted several systemic challenges which were further explored at the HSJ Medicines Forum in October 2024.
These discussions exposed an urgent need for reform in how medicines optimisation is approached. It is clear that without strategic intervention, inequalities in patient care will only widen, leading to a detrimental impact on public health outcomes. The following article details some of the key takeaways from the events, as well as a proposed path forward for the NHS and industry leaders.
Learn more by reading the full thought leadership article:
Behind Every Prescription Is a Person: Reframing Medicines Optimisation for Patient-Centric Impact in the NHS
In June 2025 the third instalment in this series of collaborations commenced. This roundtable event brought together a variety of key pharmacy stakeholders to debate and discuss the value of medicines in the patient pathway. Of particular focus was understanding patient centric access to medicines and how to ensure that services are delivered with patients in mind.
Part of the outcome of this round table discussion was timely reminder that medicines should be seen not as a controllable cost but as a strategic asset. Optimisation is not simply about reducing waste. It is about embedding medicines into the design of the patient care pathways, supporting patients to use them effectively, and recognising their role in driving population health.
Learn more by reading the full thought leadership article:
MOC1010347C4_OCT2025
© Copyright HSJ in partnership with Aspire Pharma Limited
